News
Dr. Breelyn Wilky discusses challenges that patients with GIST face and shares advice with those who feel overwhelmed by the ...
Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.
A cancer survivor celebrates being cancer-free, reflecting on her journey through breast cancer and treatments. The couple's ...
Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the ...
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...
In a candid interview with CURE, Terry Gillespie reflects on how her definition of survivorship has evolved from her lung ...
A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.
Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.
A subtle ad about breast cancer self-checks led me to reflect on my own experience and the complex role of pharmaceutical companies in awareness.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results